|
Malignant neoplasm of liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
To assess the association of TM6SF2 rs58542926 T/C gene polymorphism with liver cancer, we performed the current meta-analysis.
|
31752753 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
To assess the association of TM6SF2 rs58542926 T/C gene polymorphism with liver cancer, we performed the current meta-analysis.
|
31752753 |
2019 |
|
Adenoma of large intestine
|
|
0.010 |
GeneticVariation
|
BEFREE |
We demonstrated the significant association between TM6SF2 rs58542926 polymorphism and the risk of NAFLD and NAFLD&CRA in a Chinese Han population.
|
30727943 |
2019 |
|
Adult Liver Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
To assess the association of TM6SF2 rs58542926 T/C gene polymorphism with liver cancer, we performed the current meta-analysis.
|
31752753 |
2019 |
|
Adrenoleukodystrophy
|
|
0.010 |
GeneticVariation
|
BEFREE |
The adiponutrin (PNPLA3) p.I148M and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K variants represent major genetic risk factors for progressive liver injury in nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) and chronic viral hepatitis.
|
30161167 |
2018 |
|
Chronic viral hepatitis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The adiponutrin (PNPLA3) p.I148M and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K variants represent major genetic risk factors for progressive liver injury in nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) and chronic viral hepatitis.
|
30161167 |
2018 |
|
Primary sclerosing cholangitis
|
|
0.010 |
GeneticVariation
|
BEFREE |
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
|
30161167 |
2018 |
|
Posterior subcapsular cataract
|
|
0.010 |
GeneticVariation
|
BEFREE |
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
|
30161167 |
2018 |
|
Diabetes Mellitus
|
|
0.010 |
GeneticVariation
|
BEFREE |
A glutamate-to-lysine variant (rs58542926-T) in transmembrane 6 superfamily member 2 (<i>TM6SF2</i>) is associated with increased fatty liver disease and diabetes in conjunction with decreased cardiovascular disease risk.
|
28539357 |
2017 |
|
Diabetes
|
|
0.010 |
GeneticVariation
|
BEFREE |
A glutamate-to-lysine variant (rs58542926-T) in transmembrane 6 superfamily member 2 (<i>TM6SF2</i>) is associated with increased fatty liver disease and diabetes in conjunction with decreased cardiovascular disease risk.
|
28539357 |
2017 |
|
HCV coinfection
|
|
0.010 |
GeneticVariation
|
BEFREE |
In HIV/HCV coinfection the TM6SF2 E167K variant is an independent predictor of severe fibrosis, but appears to be independently associated with severe steatosis only for patients with a non-3 HCV genotype.
|
27784963 |
2016 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
|
0.010 |
GeneticVariation
|
BEFREE |
In HIV/HCV coinfection the TM6SF2 E167K variant is an independent predictor of severe fibrosis, but appears to be independently associated with severe steatosis only for patients with a non-3 HCV genotype.
|
27784963 |
2016 |
|
Hepatitis B, Chronic
|
|
0.010 |
GeneticVariation
|
BEFREE |
The TM6SF2 E167K substitution promotes steatosis and lipid abnormalities in part by altering TM6SF2 and microsomal triglyceride transfer protein expression and differentially impacts CHC and chronic hepatitis B viral load, while effects on fibrosis are marginal.(Hepatology 2016;64:34-46).
|
26822232 |
2016 |
|
Liver Cirrhosis, Alcoholic
|
|
0.010 |
GeneticVariation
|
BEFREE |
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
|
26493626 |
2016 |
|
Insulin resistance syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
The I148M variant in PNPLA3 and the E167K variant in TM6SF2 are both associated with increased liver fat content, but not features of the metabolic/insulin resistance syndrome.
|
27432073 |
2016 |
|
Hypertriglyceridemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We conclude that the E167K variant in TM6SF2 is associated with a distinct subtype of NAFLD, characterized by preserved insulin sensitivity with regard to lipolysis, hepatic glucose production and lack of hypertriglyceridemia despite a clearly increased LFAT content.
|
25457209 |
2015 |
|
Dyslipidemias
|
|
0.010 |
GeneticVariation
|
BEFREE |
A common non-synonymous polymorphism, E167K, in transmembrane six superfamily member 2 (TM6SF2) gene has been recently associated with an increased hepatic triglyceride content, dyslipidemia and liver fibrosis in NAFLD patients.
|
25581573 |
2015 |
|
Myocardial Infarction
|
|
0.010 |
GeneticVariation
|
BEFREE |
One variant in TM6SF2 (encoding p.Glu167Lys), residing in a known genome-wide association study locus for lipid traits, influences total cholesterol levels and is associated with myocardial infarction.
|
24633158 |
2014 |
|
Alcoholic Liver Diseases
|
|
0.020 |
GeneticVariation
|
BEFREE |
SNPs in genes linked to HCC (DEPDC5, GRIK1, KIF1B, STAT4, MICA, DLC1, DDX18) or to liver damage (PNPLA3-rs738409, TM6SF2-rs58542926) in GWAS were genotyped in discovery cohorts including 1,020 HCC, 2,021 controls with chronic liver disease and 2,484 healthy individuals and replication was performed in prospective cohorts of cirrhotic patients with alcoholic liver disease (ALD, n = 249) and hepatitis C (n = 268).
|
30289982 |
2019 |
|
Chronic liver disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
These results suggested that TM6SF2 rs58542926 could be used to identify individuals at higher susceptibility to chronic liver disease, especially for HCC, cirrhosis, ALD, and NAFLD.
|
31309745 |
2019 |
|
Hepatitis B
|
|
0.020 |
GeneticVariation
|
BEFREE |
T allele of TM6SF2 rs58542926 was more prevalent in NBNC-HCC (24%) than in healthy controls (8%), HBV-HCC (10%) and HCV-HCC (12%) (P < 0.001).
|
30506232 |
2019 |
|
Chronic liver disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
SNPs in genes linked to HCC (DEPDC5, GRIK1, KIF1B, STAT4, MICA, DLC1, DDX18) or to liver damage (PNPLA3-rs738409, TM6SF2-rs58542926) in GWAS were genotyped in discovery cohorts including 1,020 HCC, 2,021 controls with chronic liver disease and 2,484 healthy individuals and replication was performed in prospective cohorts of cirrhotic patients with alcoholic liver disease (ALD, n = 249) and hepatitis C (n = 268).
|
30289982 |
2019 |
|
Alcoholic Liver Diseases
|
|
0.020 |
GeneticVariation
|
BEFREE |
The adiponutrin (PNPLA3) p.I148M and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K variants represent major genetic risk factors for progressive liver injury in nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) and chronic viral hepatitis.
|
30161167 |
2018 |
|
Nonalcoholic Steatohepatitis
|
|
0.020 |
GeneticVariation
|
BEFREE |
The rs738409 and rs58542926 variants, but not rs641738, were associated not only with non-alcoholic steatohepatitis (NASH) (odds ratio [OR], 2.00; 95% confidence interval [CI], 1.46-2.73 and OR, 1.91; 95% CI, 1.04-3.51) but also with significant fibrosis (≥ F2) (OR, 1.53; 95% CI, 1.11-2.11 and OR, 1.88; 95% CI, 1.02-3.46) in NAFLD, even after adjustment for metabolic risk factors.
|
29193269 |
2018 |
|
Pseudohyperkalemia Cardiff
|
|
0.020 |
GeneticVariation
|
BEFREE |
The TM6SF2 E167K substitution promotes steatosis and lipid abnormalities in part by altering TM6SF2 and microsomal triglyceride transfer protein expression and differentially impacts CHC and chronic hepatitis B viral load, while effects on fibrosis are marginal.(Hepatology 2016;64:34-46).
|
26822232 |
2016 |